Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed) | PAR 21 229

Opportunity Information: Apply for PAR 21 229

The NIH funding opportunity "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" (PAR-21-229) is designed to tackle a major bottleneck in modern human genetics: researchers can now identify huge numbers of DNA variants linked to congenital and childhood-onset conditions, but it is still difficult to determine which variants actually change biology in a way that causes disease. With genotyping and next-generation sequencing producing increasingly large datasets, especially from pediatric cohorts, the program focuses on moving beyond statistical or observational associations and toward evidence that specific variants have real functional effects tied to measurable birth-defect phenotypes.

A central motivation for the initiative is the rapid growth of publicly accessible genomic and phenotypic resources. The announcement highlights that extensive datasets from birth defects and pediatric cohorts are already available to the research community through well-known repositories such as dbGaP, the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive, and ClinGen. The opportunity is essentially encouraging investigators to mine and prioritize variants coming from these kinds of resources (as well as from their own sequencing efforts), then apply rigorous experimental strategies to test what those variants do. The emphasis is on bridging the gap between "this variant looks interesting on paper" and "this variant demonstrably disrupts a pathway, a developmental process, or a molecular function in a way that aligns with the observed disorder."

In terms of scientific scope, the program is centered on congenital and pediatric-onset disorders, explicitly including structural birth defects (SBDs), intellectual and developmental disabilities (IDDs), and inborn errors of metabolism (IEMs). These categories span a wide range of mechanisms, from early embryonic development and organogenesis to neuronal development and metabolic pathway disruption, so the program is broadly relevant across developmental biology, human genetics, pediatrics, molecular biology, systems biology, and related fields. The common thread is that the projects should focus on screening, functional validation, and characterization of genomic variants associated with these conditions, rather than simply identifying additional variants or reporting new statistical associations.

The types of approaches encouraged are flexible and can be single-method or combined in "multi-pronged" strategies, depending on what is appropriate for the gene, variant type, and phenotype. The announcement explicitly mentions in-silico tools, appropriate animal models, and in vitro systems. In practice, this points to work such as computational prioritization and annotation of candidate variants, followed by experimental testing in cellular models (including genome editing, expression studies, protein function assays, pathway readouts, organoids, or other relevant cell-based systems) and/or model organisms that can capture developmental phenotypes. The underlying expectation is that applicants will select the systems and assays best suited to demonstrate causality or mechanism, and that the results will help clarify which variants are truly functional, how they act, and how they connect to the observed birth-defect outcomes.

Administratively, this is an NIH R01 research project grant opportunity under the "Clinical Trial Not Allowed" designation, meaning the proposed research should not include a clinical trial as defined by NIH policy. It falls under a discretionary grant mechanism in the Health, Income Security and Social Services category, and it lists CFDA numbers 93.121, 93.351, and 93.865. The posting indicates an award ceiling of $499,999. The original closing date provided is 2025-05-07, and the opportunity was created on 2021-05-05.

Eligibility is broad and includes many common applicant types: state, county, and local governments; special districts; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities. The announcement also specifically calls out additional eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, non-domestic (non-U.S.) entities (foreign organizations), regional organizations, Indian/Native American tribal governments other than federally recognized, and U.S. territories or possessions. In other words, NIH is signaling that it wants wide participation and that the work can be carried out across many institutional settings, including international and underserved-serving institutions where appropriate.

Taken together, the opportunity is best understood as a translationally oriented genetics and developmental biology program that emphasizes functional evidence. It aims to turn the growing stockpile of candidate birth-defect variants into well-validated variant-phenotype relationships and clearer mechanistic understanding, using modern computational methods and experimental models. The practical payoff is improved interpretation of genomic variants relevant to pediatric congenital conditions, which can ultimately support better diagnosis, variant classification, and biological insight into how these disorders arise, even though the funded projects themselves must remain non-clinical-trial research.

• The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.351, 93.865.
• This funding opportunity was created on 2021-05-05.
• Applicants must submit their applications by 2025-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $499,999.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 21 229

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: